Noninvasive tests are being explored as a key method for identifying metabolic dysfunction-associated steatotic liver disease, also known as MASH, in primary care settings. Research and advancements in diagnostic pathways and therapeutic strategies for MASH are ongoing, with various studies and technologies being developed to improve diagnosis and care. The development of noninvasive diagnostic tools, such as breath tests and blood sample analysis, may help identify patients with MASH and improve treatment outcomes.